Viking Therapeutics (VKTX) to Release Earnings on Wednesday

Key Points

• Q1 2026 results are due after the market closes on Wednesday, April 22, 2026 (earnings call at 4:30 PM ET), with analysts expecting EPS of ($1.01); Viking missed the prior quarter (reported ($1.38) vs. estimate ($0.89)).
• The stock trades near $35.52 with a market cap of $4.12B and a one‑year range of $21.23–$43.15, and Wall Street holds a “Moderate Buy” consensus with an average price target of $94.22 amid mixed analyst ratings.
• Insider Neil William Aubuchon purchased 4,475 shares at $33.50 on March 10; insiders own 5.30% and institutional investors hold 76.03%, with large recent stake increases by firms like Two Sigma and Ameriprise.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) is expected to be releasing its Q1 2026 results after the market closes on Wednesday, April 22nd. Analysts expect Viking Therapeutics to post earnings of ($1.01) per share for the quarter. Interested persons are encouraged to explore the company's upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Wednesday, April 22, 2026 at 4:30 PM ET.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 11th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.49). During the same quarter last year, the firm earned ($0.32) EPS. On average, analysts expect Viking Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viking Therapeutics Stock Performance

NASDAQ VKTX opened at $35.52 on Wednesday. The firm has a 50 day simple moving average of $32.59 and a 200-day simple moving average of $33.77. Viking Therapeutics has a one year low of $21.23 and a one year high of $43.15. The firm has a market cap of $4.12 billion, a price-to-earnings ratio of -11.17 and a beta of 0.83.

Insider Transactions at Viking Therapeutics

In other news, insider Neil William Aubuchon purchased 4,475 shares of the firm's stock in a transaction that occurred on Tuesday, March 10th. The stock was bought at an average price of $33.50 per share, for a total transaction of $149,912.50. Following the completion of the purchase, the insider directly owned 4,475 shares of the company's stock, valued at $149,912.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 5.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VKTX. Two Sigma Investments LP lifted its stake in Viking Therapeutics by 58.7% in the third quarter. Two Sigma Investments LP now owns 2,085,487 shares of the biotechnology company's stock worth $54,807,000 after acquiring an additional 771,704 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Viking Therapeutics by 41.8% in the third quarter. Ameriprise Financial Inc. now owns 2,092,840 shares of the biotechnology company's stock worth $55,000,000 after acquiring an additional 616,526 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in Viking Therapeutics by 6,315.6% in the second quarter. Cubist Systematic Strategies LLC now owns 596,650 shares of the biotechnology company's stock worth $15,811,000 after acquiring an additional 587,350 shares during the last quarter. Duquesne Family Office LLC purchased a new position in Viking Therapeutics in the second quarter worth approximately $14,556,000. Finally, Man Group plc lifted its stake in Viking Therapeutics by 2,628.8% in the fourth quarter. Man Group plc now owns 260,301 shares of the biotechnology company's stock worth $9,157,000 after acquiring an additional 250,762 shares during the last quarter. Hedge funds and other institutional investors own 76.03% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on VKTX. Weiss Ratings reissued a "sell (d-)" rating on shares of Viking Therapeutics in a research note on Wednesday, January 21st. Zacks Research raised shares of Viking Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, February 18th. Morgan Stanley reissued an "overweight" rating and issued a $99.00 price objective on shares of Viking Therapeutics in a research note on Thursday, February 12th. Wolfe Research began coverage on shares of Viking Therapeutics in a research note on Thursday, March 26th. They issued a "peer perform" rating for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $102.00 price objective on shares of Viking Therapeutics in a research note on Monday, March 23rd. Four analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $94.22.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company's pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company's lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.